Major Companies in Japan Eczema Market | Key Players & Insights 2026

Japan Eczema Market Overview

According to 6Wresearch, the Japan eczema market is characterized by a strong demand for high-efficacy systemic treatments as patients and clinicians seek alternatives to the "rebound effect" of long-term steroid use. The market is evolving from simple symptom management to a model of precision immunology. Manufacturers are increasingly focusing on patient quality of life (QoL) by developing subcutaneous biologics and oral small-molecule inhibitors that provide rapid itch relief and skin clearance, even in severe or treatment-resistant situations.

Competitive Landscape

The competitive landscape in Japan is a strategic blend of global immunology leaders and specialized domestic dermatology powerhouses. While global corporations dominate the biologics market, domestic companies leverage deep-rooted relationships with local dermatologists and extensive distribution networks to dominate the topical and specialty pharmaceutical categories.

Below is a list of leading players in the Japan Eczema Market:

1. Sanofi S.A.

A dominant force in the market with its IL-4/IL-13 inhibitor, Dupixent, which has set a new standard for systemic treatment in moderate-to-severe atopic dermatitis across Japan.

2. Regeneron Pharmaceuticals, Inc.

Collaborates closely with Sanofi to bring groundbreaking monoclonal antibodies to the Japanese clinical landscape, focusing on high-science metabolic and inflammatory care.

3. AbbVie Inc.

A global leader in immunology, AbbVie has rapidly captured market share in Japan with its JAK inhibitor, Rinvoq, offering patients a powerful oral alternative for skin clearance.

4. Eli Lilly and Company

Leverages nearly 150 years of heritage to provide advanced systemic therapies that target specific inflammatory pathways responsible for chronic eczema.

5. Pfizer Inc.

Contributes to the market with innovative JAK inhibitors and a broad portfolio of topical anti-inflammatories designed for various stages of eczema severity.

6. Maruho Co., Ltd.

As Japan’s leading dermatology-focused firm, Maruho maintains a vast portfolio of topicals and moisturizers, serving as a foundational player in Japanese eczema management.

7. Torii Pharmaceutical Co., Ltd.

A key domestic player that has strengthened its position through strategic partnerships to market novel JAK inhibitors specifically tailored for the Japanese population.

8. LEO Pharma A/S

A specialty pharmaceutical company dedicated entirely to dermatology, bringing European expertise in biologics and topicals to the Japanese market since its local establishment in 2010.

9. Mitsubishi Tanabe Pharma Corporation

One of the oldest pharmaceutical companies in the world, providing essential anti-inflammatory treatments and contributing to a comprehensive chronic care model.

10. Kyowa Kirin Co., Ltd.

Specializes in biotechnology and antibody-based research, focusing on the R&D of novel treatments for immunological and allergic skin conditions.

11. Daiichi Sankyo Company, Limited

Leverages a deep heritage in metabolic and cardiovascular health to produce high-compliance treatments for systemic inflammatory conditions.

12. Takeda Pharmaceutical Company Limited

While a global giant, Takeda remains a critical distribution partner for various dermatology treatments, ensuring wide patient access across Japan’s rural and urban sectors.

13. Otsuka Pharmaceutical Co., Ltd.

Focuses on holistic health and provides supportive topical therapies that complement systemic eczema treatments for overall skin barrier restoration.

14. Sun Pharma Japan Ltd.

A global leader in specialty generics, providing cost-effective topical steroids and anti-infectives essential for managing secondary eczema complications.

15. Shionogi & Co., Ltd.

Known for its research-intensive approach, Shionogi contributes to the market through innovative small-molecule drugs aimed at chronic inflammatory pathways.